What is Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women, characterized by the abnormal growth of smooth muscle-like cells that invade and damage lung tissue, airways, and blood vessels. This condition can lead to the formation of lung cysts, recurrent pneumothorax (collapsed lungs), and a decline in respiratory function over time.

What is Lymphangioleiomyomatosis and how does it affect the body?

Lymphangioleiomyomatosis, often referred to simply as LAM, is a multisystem disorder. While it primarily targets the lungs, the abnormal, tumor-like LAM cells can also affect the lymphatic system and kidneys. In the lungs, these cells destroy healthy tissue by creating cysts, which impairs the lung's ability to exchange oxygen effectively. Beyond the lungs, patients may develop lymphangioleiomyomas (fluid-filled sacs in the abdomen or chest) or angiomyolipomas, which are benign but potentially bleeding-prone tumors in the kidneys.

Who is typically affected by Lymphangioleiomyomatosis?

Lymphangioleiomyomatosis is an extremely rare condition, with prevalence estimates suggesting it affects approximately 3 to 7 per million women worldwide. It is almost exclusively diagnosed in females, typically during their childbearing years, with an average age of onset around 30 to 35. Because the condition is often misdiagnosed as asthma or chronic obstructive pulmonary disease (COPD), the true prevalence may be higher than current clinical data reflects. Currently, our DiseaseMaps.org community includes 9 members who have shared their personal experiences with Lymphangioleiomyomatosis.

What causes this condition?

The underlying mechanism of Lymphangioleiomyomatosis involves a mutation in the TSC1 or TSC2 genes, which normally regulate cell growth. When these genes are mutated, the "brakes" on cell proliferation are removed, leading to the uncontrolled growth of LAM cells. The condition is categorized into two forms:

• Sporadic LAM: Occurs randomly in women with no family history of the disease.


• Tuberous Sclerosis Complex (TSC)-associated LAM: Occurs in patients who have a broader genetic disorder called Tuberous Sclerosis Complex.

Key facts that differentiate Lymphangioleiomyomatosis from other lung diseases

Unlike common obstructive lung diseases, Lymphangioleiomyomatosis is distinguished by the specific presence of LAM cells that are sensitive to hormonal changes, particularly estrogen. This hormonal link explains why the disease predominantly manifests in women. Key clinical markers include:

1. The presence of multiple, thin-walled, round cysts throughout the lung parenchyma visible on high-resolution CT scans.


2. A significantly higher risk of spontaneous pneumothorax compared to other interstitial lung diseases.


3. The potential for chylous pleural effusions, where lymphatic fluid leaks into the space surrounding the lungs.

Next steps

• Consult a pulmonologist who specializes in interstitial lung disease or rare respiratory disorders.


• Request a high-resolution computed tomography (HRCT) scan if you suspect symptoms like unexplained shortness of breath.


• Connect with the Lymphangioleiomyomatosis community on DiseaseMaps.org to share experiences and access peer support.


• Inquire with your medical team about clinical trials or specialized registries for LAM patients.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases (GARD) Information Center: "Lymphangioleiomyomatosis"


• Orphanet: "Lymphangioleiomyomatosis (ORPHA:527)"


• The LAM Foundation: "About LAM" (thelamfoundation.org)


• OMIM (Online Mendelian Inheritance in Man): "Lymphangioleiomyomatosis (Entry #606690)"